444 Biol Phys 1994;28:33-7. 46. Crawford ED, Batuello JT, Snow P, Gamito EJ, McLeod DG, Partin AW, et al. The use of artificial intelligence technology to predict lymph node spread in men with clinically localized pros- tate carcinoma. Cancer 2000;88:2105-9. 47. Batuello JT, Gamito EJ, Crawford ED, Han M, Partin AW, McLeod DG, et al. Artificial neural network model for the assess- ment of lymph node spread in patients with clinically localized prostate cancer. Urology 2001;57:481-5. 48. Han M, Snow PB, Brandt JM, Partin AW. Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. Cancer 2001;91(8 Suppl):1661-6. 49. Poulakis V, Witzsch U, De Vries R, Emmerlich V, Meves M, Altmannsberger HM, et al. Preoperative neural network using combined magnetic resonance imaging variables, prostate specif- ic antigen and Gleason score to predict prostate cancer stage. J Urol 2004;172:1306-10. 50. Karam JA, Svatek RS, Karakiewicz PI, Gallina A, Roehrborn CG, Slawin KM, et al. Use of preoperative plasma endoglin for pre- diction of lymph node metastasis in patients with clinically lo- calized prostate cancer. Clin Cancer Res 2008;14:1418-22. 51. Wang L, Hricak H, Kattan MW, Schwartz LH, Eberhardt SC, Chen HN, et al. Combined endorectal and phased-array MRI in the prediction of pelvic lymph node metastasis in prostate cancer. AJR Am J Roentgenol 2006;186:743-8. 52. Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001;58:843-8. 53. Briganti A, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, et al. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prosta- tectomy and an extended pelvic lymphadenectomy. Eur Urol 2006;49:1019-26. 54. Conrad S, Graefen M, Pichlmeier U, Henke RP, Erbersdobler A, Hammerer PG, et al. Prospective validation of an algorithm with systematic sextant biopsy to predict pelvic lymph node metastasis in patients with clinically localized prostatic carcinoma. J Urol 2002;167:521-5. 55. Briganti A, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenec- tomy in patients with clinically localized prostate cancer. BJU Int 2006;98:788-93. 56. Wawroschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, et al. Prostate lymphoscintigraphy and radio-guided surgery for sentinel lymph node identification in prostate cancer. Technique and results of the first 350 cases. Urol Int 2003;70: 303-10. 57. Song C, Kang T, Lee MS, Ro JY, Lee SE, Lee E, et al. Clinico-patho- logical characteristics of prostate cancer in Korean men and nomograms for the prediction of the pathological stage of the clin- ically localized prostate cancer: a multi-institutional update. Korean J Urol 2007;48:125-30. 58. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatec- tomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280: 969-74. 59. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE. Is pelvic lymph node dissection necessary in patients with a serum PSA＜10ng/ml undergoing radical prostatectomy Korean J Urol 2011;52:437-445 Joung et al for prostate cancer? Eur Urol 2006;50:272-9. 60. Bhatta-Dhar N, Reuther AM, Zippe C, Klein EA. No difference in six-year biochemical failure rates with or without pelvic lymph node dissection during radical prostatectomy in low-risk patients with localized prostate cancer. Urology 2004;63:528-31. 61. Grossfeld GD, Chang JJ, Broering JM, Li YP, Lubeck DP, Flanders SC, et al. Under staging and under grading in a con- temporary series of patients undergoing radical prostatectomy: results from the Cancer of the Prostate Strategic Urologic Research Endeavor database. J Urol 2001;165:851-6. 62. Golimbu M, Provet J, Al-Askari S, Morales P. Radical prostatec- tomy for stage D1 prostate cancer. Prognostic variables and re- sults of treatment. Urology 1987;30:427-35. 63. Catlona WJ, Miller DR, Kavoussi LR. Intermediate-term surviv- al results in clinically understaged prostate cancer patients fol- lowing radical prostatectomy. J Urol 1988;140:540-3. 64. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation fol- lowing radical prostatectomy. JAMA 1999;281:1591-7. 65. Pagliarulo V, Hawes D, Brands FH, Groshen S, Cai J, Stein JP, et al. Detection of occult lymph node metastases in locally ad- vanced node-negative prostate cancer. J Clin Oncol 2006;24: 2735-42. 66. Ferrari AC, Stone NN, Kurek R, Mulligan E, McGregor R, Stock R, et al. Molecular load of pathologically occult metastases in pel- vic lymph nodes is an independent prognostic marker of bio- chemical failure after localized prostate cancer treatment. J Clin Oncol 2006;24:3081-8. 67. Terakawa T, Miyake H, Kurahashi T, Furukawa J, Takenaka A, Fujisawa M. Improved sensitivity for detecting micrometastases in pelvic lymph nodes by real-time reverse transcriptase polymer- ase chain reaction (RT-PCR) compared with conventional RT-PCR in patients with clinically localized prostate cancer un- dergoing radical prostatectomy. BJU Int 2009;103:1074-8. 68. Daneshmand S, Quek ML, Stein JP, Lieskovsky G, Cai J, Pinski J, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004;172:2252-5. 69. Allaf ME, Palapattu GS, Trock BJ, Carter HB, Walsh PC. Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer. J Urol 2004;172:1840-4. 70. Joslyn SA, Konety BR. Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer. Urology 2006;68:121-5. 71. Boorjian SA, Thompson RH, Siddiqui S, Bagniewski S, Bergstralh EJ, Karnes RJ, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate can- cer in the prostate specific antigen era. J Urol 2007;178:864-70. 72. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term followup. J Urol 2004;172:1860-4. 73. Masterson TA, Bianco FJ Jr, Vickers AJ, DiBlasio CJ, Fearn PA, Rabbani F, et al. The association between total and positive lymph node counts, and disease progression in clinically localized pros- tate cancer. J Urol 2006;175:1320-4. 74. DiMarco DS, Zincke H, Sebo TJ, Slezak J, Bergstralh EJ, Blute ML. The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific an- tigen era. J Urol 2005;173:1121-5. 75. Murphy AM, Berkman DS, Desai M, Benson MC, McKiernan JM, Badani KK. The number of negative pelvic lymph nodes removed